$SYK

King Debra sold $278K of SYK

King Debra (See Remarks) sold 826 shares of STRYKER CORP (SYK) at $336.30 ($0.28M total) on 2026-08-18.

Original reporting
SEC EDGAR · King Debra
Published Aug 18, 2026, 8:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 10:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SYK
Neutral
medium confidence
Mentioned
$SYK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SYKNeutralLow
01

Why it matters

The only new fact is the reported sale details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may briefly reassess sentiment around SYK due to an insider sale, but there is no accompanying fundamental catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the filing lacks any stated reason or linkage to company fundamentals.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-18

Background

The article is an SEC Form 4 insider transaction disclosure for Stryker (SYK).

Company-level read

Ticker impact

$SYKNeutralMedium confidence
Context

Stryker Form 4 shows officer King Debra sold 826 shares on 2026-08-18 at $336.3040, totaling $277,787.10.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and typically fades unless accompanied by other disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction. The article provides transaction size, price, and post-sale holdings, but no new company-specific operational or financial information.

Market effects

No clear sector read-through from a single insider sale at this scale.

None.

None.

Counterpoint

Absence of a disclosed 10b5-1 plan can be interpreted by some traders as less “scheduled,” potentially adding short-term bearish sentiment.

Key entities

  • STRYKER CORP

    Company whose insider transaction was disclosed via Form 4.

  • King Debra

    Officer who sold 826 shares on 2026-08-18.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SYKHighAI 8/10

Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS

Stryker (SYK) shares fell $26.70 (-8.8%) on Sept. 8, 2026, after its CFO revealed persisting manufacturing issues in its Peripheral Vascular unit, acquired from Inari Medical. The firm Hagens Berman is investigating potential disclosure violations. The issue, initially thought resolved, led to lost sales and backorders, with the CFO stating it will continue into Q4.

$SYKLow

Why Stryker (SYK) Stock Is Down Today

Stryker (SYK) shares fell 6.9% after management at a healthcare conference indicated longer-than-expected supply chain issues and slower joint replacement recovery, potentially affecting revenue. The company had reported solid Q2 results in July. Insider sales and mixed hedge fund activity were also noted.

$SYKMed

Stryker stock drops 7.7% as supply problems and weak joint replacement sales hit outlook

Stryker shares dropped 7.7% on Tuesday due to ongoing supply chain issues and weaker-than-expected joint replacement sales. CFO Preston Wells stated that manufacturing problems will persist into Q4, impacting sales growth. The company also missed recovery expectations in its joint replacement business, citing seasonal weakness. Investors are concerned about the timing of a broader recovery.